Device Trial Radar · NCT06111365
Pivotal Observational CHLOE Study
Last checked: Nov 19, 2026Latest source record: Mar 19, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
59
Actual
Start
Jan 22, 2024
Primary completion
Aug 12, 2024
Study completion Aug 12, 2024
Sponsor
- Lead sponsor
- FairtilityNot on our public-company list
- Sponsor type
- Industry
- First posted
- Nov 1, 2023
Design
- Study type
- Observational
- FDA-regulated device
- Yes
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This pivotal study is an observational, prospective assessment, multi-center, databank based, clinical study aimed to evaluate the performance of CHLOE™ algorithm in prediction of blastocyst formation.
Conditions
- IVF
Interventions
CHLOEDevice
the system will provide to the user a "CHLOE™ score", which is a blastocyst development prediction value, a discrete grading for blastocyst associated with the likelihood of the embryo reaching the blastocyst stage at Day 5
Primary outcomes
What the sponsor says the trial is designed to measure.
- The Odds Ratio (OR) for the adjunct prediction of blastulation is required to be statistically significantly greater than 1Time frame: day 5
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Weill Cornell Medicine
New York, New York
Cleveland Clinic Fertility
Cleveland, Ohio
Dallas Fertility Center
Dallas, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.